AdVanceXP male sling: 2-year results of a multicentre study

Bauer, Ricarda M.; Gozzi, Christian; Klehr, Benedikt; Kretschmer, Alexander; Grabbert, Markus; Rehder, Peter; Maÿ, F.; Stief, Christian G.; Gebhartl, Peter; Homberg, Roland

doi:10.1007/s00345-015-1731-0

Cited by 25 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there have been two comparative studies showing that those changes did not significantly alter the efficacy of the AdVanceXP sling compared with the conventional AdVance sling [4,5]. The longest follow-up after AdVanceXP implantation is 2 years and this has recently been reported in a prospective multicentre setting [6]. In the present study, we provide results >30 months after AdVanceXP implantation in a single-centre study and therefore give new insights into long-term durability and safety.…”

Section: Discussionmentioning

confidence: 61%

“…In a recent prospective multicentre study, including data from 94 consecutive patients and a maximum follow-up of 2 years, a cure rate (0 pads and 0-5 g urine loss per day) of 73.1% could be observed. The cure-and-improved rate was 92.7% [6].…”

Section: Discussionmentioning

confidence: 88%

“…To better accommodate the male pelvic anatomy and an increased patient BMI, the sling arm length has been increased and the helical tunnelling needle shape has been updated. Several studies have evaluated outcomes after AdVanceXP implantation, with a follow-up of up to 2 years [4][5][6]. The aim of the present prospective single-centre study was to analyse the outcomes of AdVanceXP sling implantation after a mean follow-up of almost 3 years.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mid‐term outcomes after AdVanceXP male sling implantation

et al. 2016

Self Cite

View full text Add to dashboard Cite

ObjectiveTo describe efficacy and safety of the AdVanceXP (Boston Scientific, Marlborough, MA, USA) retrourethral transobturator male sling after a mean follow‐up of almost 3 years.Patients and MethodsA total of 41 patients underwent AdVanceXP implantation between July 2010 and March 2012 by a single surgeon. Patients were prospectively evaluated at baseline, after a mean follow‐up of 12months and after an individual maximum follow‐up. Efficacy was evaluated by daily pad usage, 24‐h pad testing, and validated questionnaires (International Consultation on Incontinence questionnaire [ICIQ]). Patient satisfaction was determined using the Patient's Global Impression of Improvement score; quality of life was evaluated using the International Quality of Life (IQOL) score. Patients needing 0 or 1 safety pad with a daily urine loss <8 g were classified as cured. To assess the changes in outcome over time, a Wilcoxon signed‐rank test was used. A P value <0.05 was taken to indicate statistical significance.ResultsThe mean ± sd follow‐up was 33.1 ± 8.1 months. A total of four patients (9.8%) were lost to follow‐up. At follow‐up, 56.1% of patients used 0 or 1 dry safety pad, 17.1% used 1 pad, and 17.1% used 2 pads. Mean pad use was 0.6 pads per day (P < 0.001 vs baseline) with a mean urine loss of 14 g per day. After nearly 3 years, 46.3% of the patients could be classified as cured and 29.3% could be classified as improved. When comparing respective outcomes after 1 and 3 years, no significant changes in mean daily pad use (0.8 at 1 year; P = 1.000), in ICIQ score (5.0 at 3 years vs 5.2 at 1 year; P = 0.500), or in IQOL score (89.2 at 3 years vs 86.8 at 1 year; P = 0.500) were observed. Patients lost less urine based on 24‐h pad testing after nearly 3 years (14 g at 3 years vs 28 g at 1 year; P = 0.106). Subgroup analyses showed no significant differences in efficacy in patients who had previously received radiotherapy or in patients with mild preoperative incontinence. Between 1 and 3 years postoperatively, no complications were detected.ConclusionsThe present study had the longest follow‐up for AdVanceXP to date and is the first to show a high efficacy even after a mean follow‐up of almost 3 years. The results indicate that late‐onset complications are rare after AdVanceXP implantation.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mid‐term outcomes after AdVanceXP male sling implantation

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cure rates for the AdVance ® sling are reported to be between 54.1 and 92.3% [4,13,[15][16][17], although definitions of cure differ in these publications. In this study, no patient was cured and only 61.9% reported an improvement of incontinence, which is in line with the results of the study by Sacco et al [14].…”

Section: Discussionmentioning

confidence: 99%

“…According to the ICIQ-SF, 11 (57%) reported a severe or very severe incontinence postoperatively, 6 (32%) reported moderate and only 2 (11%) minor urinary incontinence. The outcome parameters with respect to efficacy are presented in Table 2 in comparison to the results of the AdVance ® (AMS Men's Health/Boston Scientific, USA) male sling [13]. The mean pain scores were 0.2 ± 0.5 for the perineum, 0.15 ± 0.5 for the genitals, 0.15 ± 0.5 for the symphysis, and 0.3 ± 07 for the inguinal groin.…”

Section: Follow-upmentioning

confidence: 99%

The TiLOOP® Male Sling: Did We Forejudge

Hüsch

Kretschmer²,

Thomsen³

et al. 2017

Urol Int

Self Cite

View full text Add to dashboard Cite

Introduction: To evaluate the safety and efficacy of the TiLOOP® male sling (pfm medical, Cologne, Germany) used in the treatment for male stress urinary incontinence (SUI). Material and Methods: We retrospectively evaluated a total of 34 patients with a TiLOOP® male sling. Perioperative complication rates were assessed and validated questionnaires were prospectively evaluated to assess quality of life and satisfaction rate. Outcome and complication rates were analysed by using descriptive statistics. Correlation of continence outcome and risk factors was performed with the chi-square test. A p value below 0.05 was considered statistically significant. Results: The majority of patients (70.6%) were diagnosed with mild or moderate male SUI. During surgery, one instance (2.9%) of intraoperative urethral injury was observed. There were no immediate postoperative complications. The mean follow-up time was 44.6 months. An improvement of male SUI was reported by 61.9% of the patients and 38.1% reported no change according the Patient Global Impression of Improvement. The mean perineal pain score was 0.5 according to the international index of pain. Conclusions: The TiLOOP® is a safe treatment option for male SUI in our cohort with a low complication rate. However, the functional outcome of the TiLOOP® was inferior when compared to the outcome of the AdVance® male sling.

show abstract